 Patient has received AnakinraKineret within the last 2 weeks prior to the Day 0 visit or is likely to receive AnakinraKineret during the course of the study Patient has a poorly controlled medical condition, such as uncontrolled diabetes, documented history of recurrent infections, unstable ischemic heart disease, class III or IV New York Heart Association Functional Classification; NYHA congestive heart failure, an ejection fraction of less than 30, recent stroke within the past 3 months, chronic leg ulcer or any other condition which, in the opinion of the investigator, would put the patient at risk if participating in the study. 